Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
— BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B – — BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds – Vancouver, British Columbia, April 19, 2023…
